These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11344170)

  • 1. Clinical review 129: Oral cholecystographic agents and the thyroid.
    Braga M; Cooper DS
    J Clin Endocrinol Metab; 2001 May; 86(5):1853-60. PubMed ID: 11344170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in thyroid function after cholecystographic contrast agents.
    Hunter AN; Meinhold H; Stockigt JR
    Aust N Z J Med; 1982 Apr; 12(2):192-5. PubMed ID: 6953963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins.
    Felicetta JV; Green WL; Huber-Smith MJ
    J Clin Endocrinol Metab; 1983 Jul; 57(1):207-12. PubMed ID: 6853679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Problems related to the radiographic study of the biliary tract using oral or intravenous contrast media. Main side effects and biochemical changes induced by the administration of contrast media].
    Limido G
    Minerva Dietol Gastroenterol; 1984; 30(1):9-15. PubMed ID: 6374500
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy.
    Bogazzi F; Miccoli P; Berti P; Cosci C; Brogioni S; Aghini-Lombardi F; Materazzi G; Bartalena L; Pinchera A; Braverman LE; Martino E
    Surgery; 2002 Dec; 132(6):1114-7; discussion 1118. PubMed ID: 12490863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uricosuric action of cholecystographic agents. A possible factor in nephrotoxicity.
    Mudge GH
    N Engl J Med; 1971 Apr; 284(17):929-33. PubMed ID: 5551801
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study.
    Bogazzi F; Bartalena L; Cosci C; Brogioni S; Dell'Unto E; Grasso L; Aghini-Lombardi F; Rossi G; Pinchera A; Braverman LE; Martino E
    J Clin Endocrinol Metab; 2003 May; 88(5):1999-2002. PubMed ID: 12727944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis.
    Martinez DS; Chopra IJ
    Panminerva Med; 2003 Mar; 45(1):53-7. PubMed ID: 12682620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical trial of oral cholecystographic agents: telepaque, sodium oragrafin and calcium oragrafin.
    Tishler JM; Gold R
    J Can Assoc Radiol; 1969 Jun; 20(2):102-5. PubMed ID: 5793435
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of three oral cholecystographic agents on laboratory data. Clinical chemical determinations and urinary tests (author's transl)].
    Kasezawa N; Tazawa R; Urushibata S; Kobayashi M
    Rinsho Byori; 1974 Jun; 22(6):440-4. PubMed ID: 4472714
    [No Abstract]   [Full Text] [Related]  

  • 11. Results obtained in comparative radiographie, clinical and clinical-chemical studies in iocetamic acid (DRC 1201) and iopanoic acid.
    Hekster RE
    Radiol Clin Biol; 1968; 37(6):338-52. PubMed ID: 5714064
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of some iodine-containing radiocontrast agents on iodothyronine secretion from the perfused canine thyroid.
    Laurberg P
    Endocrinology; 1982 Dec; 111(6):1904-8. PubMed ID: 7140639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic efficacy of oral cholecystographic agent (iopanoic acid) in the management of hyperthyroidism.
    Bal C; Nair N
    J Nucl Med; 1990 Jul; 31(7):1180-2. PubMed ID: 2194004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iopanoic acid as an adjunct to carbimazole in the management of hyperthyroidism.
    Gupta SK; Mithal A; Godbole MM
    Natl Med J India; 1992; 5(3):108-11. PubMed ID: 1304283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to tri-iodothyronine.
    Laurberg P; Boye N
    J Endocrinol; 1987 Mar; 112(3):387-90. PubMed ID: 3559449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis.
    Matrka L; Steward D; Falciglia M; Nikiforov Y
    Ear Nose Throat J; 2008 Dec; 87(12):702-4. PubMed ID: 19105148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of oral cholecystographic agents for the management of hyperthyroidism.
    Tyer NM; Kim TY; Martinez DS
    Endocr Pract; 2014 Oct; 20(10):1084-92. PubMed ID: 25100369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary-thyroid interaction: effects of thyroid hormone, non thyroidal illness and various agents on TSH secretion.
    Vagenakis AG
    Acta Med Austriaca; 1988; 15 Suppl 1():52-6. PubMed ID: 3140559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of thyroxine to triiodothyronine in the anterior pituitary gland and the influence of this process on thyroid status.
    Kaplan MM; Breitbart R
    Horm Metab Res Suppl; 1984; 14():79-85. PubMed ID: 6595194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of drug binding to human serum albumin by cholecystographic agents.
    Bertucci C; Cimitan S
    Farmaco; 2003 Sep; 58(9):901-8. PubMed ID: 13679185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.